Cover Image
市場調查報告書

Camurus AB : 產品平台分析

Camurus AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226302
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Camurus AB : 產品平台分析 Camurus AB - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 24 Pages
簡介

Camurus AB 是研究開發型製藥公司,正在開發針對具有高附加價值的治療方法用奈米規模藥物輸送系統。透過奈米規模,胜肽和蛋白質,不溶性小分子等迄今難以送達的藥劑化合物現在也能廣泛遞送。譬如他們現在正在開發製造的前列腺癌症,代謝障礙,糖尿病,牙周炎,口腔粘膜炎,生長激素分泌不全,藥物依存症候群等有效產品。

本報告提供Camurus AB 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,再加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Camurus AB的基本資料

Camurus AB概要

  • 主要資訊
  • 企業資料

Camurus AB:R&D概要

  • 主要的治療範圍

Camurus AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Camurus AB:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Camurus AB:藥物簡介

  • buprenorphine hydrochloride
  • leuprolide acetate
  • CAM-2048

Camurus AB:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Camurus AB:最近的開發平台趨勢

Camurus AB:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07568CDB

Summary

Global Markets Direct's, 'Camurus AB - Product Pipeline Review - 2015', provides an overview of the Camurus AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Camurus AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Camurus AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Camurus AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Camurus AB's pipeline products

Reasons to buy

  • Evaluate Camurus AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Camurus AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Camurus AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Camurus AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Camurus AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Camurus AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Camurus AB Snapshot
    • Camurus AB Overview
    • Key Information
    • Key Facts
  • Camurus AB - Research and Development Overview
    • Key Therapeutic Areas
  • Camurus AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Camurus AB - Pipeline Products Glance
    • Camurus AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Camurus AB - Drug Profiles
    • buprenorphine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAM-2048
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Camurus AB - Pipeline Analysis
    • Camurus AB - Pipeline Products by Target
    • Camurus AB - Pipeline Products by Route of Administration
    • Camurus AB - Pipeline Products by Molecule Type
    • Camurus AB - Pipeline Products by Mechanism of Action
  • Camurus AB - Recent Pipeline Updates
  • Camurus AB - Dormant Projects
  • Camurus AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Camurus AB, Key Information
  • Camurus AB, Key Facts
  • Camurus AB - Pipeline by Indication, 2015
  • Camurus AB - Pipeline by Stage of Development, 2015
  • Camurus AB - Monotherapy Products in Pipeline, 2015
  • Camurus AB - Out-Licensed Products in Pipeline, 2015
  • Camurus AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Camurus AB - Phase II, 2015
  • Camurus AB - Phase I, 2015
  • Camurus AB - Pipeline by Target, 2015
  • Camurus AB - Pipeline by Route of Administration, 2015
  • Camurus AB - Pipeline by Molecule Type, 2015
  • Camurus AB - Pipeline Products by Mechanism of Action, 2015
  • Camurus AB - Recent Pipeline Updates, 2015
  • Camurus AB - Dormant Developmental Projects,2015
  • Camurus AB, Other Locations

List of Figures

  • Camurus AB - Pipeline by Top 10 Indication, 2015
  • Camurus AB - Pipeline by Stage of Development, 2015
  • Camurus AB - Monotherapy Products in Pipeline, 2015
  • Camurus AB - Pipeline by Top 10 Target, 2015
  • Camurus AB - Pipeline by Top 10 Molecule Type, 2015
  • Camurus AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top